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The relationship between the severity and mortality 
of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration 
— a metaanalysis
Abstract
Introduction: There is increasing scientific interest in the possible association between hypovitaminosis D and the risk of SARS-
CoV-2 infection severity and/or mortality.  
Objective: To conduct a metanalysis of the association between 25-hydroxyvitamin D (25(OH)D) concentration and SARS-CoV-2 
infection severity or mortality.
Material and methods: We searched PubMed, EMBASE, Google scholar and the Cochrane Database of Systematic Reviews for 
studies published between December 2019 and December 2020. Effect statistics were pooled using random effects models. The 
quality of included studies was assessed with the Newcastle–Ottawa Scale (NOS). Targeted outcomes: mortality and severity 
proportions in COVID-19 patients with 25(OH)D deficiency, defined as serum 25(OH)D < 50 nmol/L.  
Results: In the 23 studies included (n = 2692), the mean age was 60.8 (SD ± 15.9) years and 53.8% were men. Results 
suggested that vitamin 25(OH)D deficiency was associated with increased risk of severe SARS-CoV-2 disease (RR 2.00; 95% 
CI 1.47–2.71, 17 studies) and mortality (RR 2.45; 95% CI 1.24–4.84, 13 studies). Only 7/23 studies reported C-reactive protein 
values, all of which were > 10 mg/L.
Conclusions 25(OH)D deficiency seems associated with increased SARS-CoV-2 infection severity and mortality. However, 
findings do not imply causality, and randomized controlled trials are required, and new studies should be designed to determine 
if decreased 25(OH)D is an epiphenomenon or consequence of the inflammatory process associated with severe forms of SARS-
CoV-2. Meanwhile, the concentration of 25(OH)D could be considered as a negative acute phase reactant and a poor prognosis 
in COVID-19 infection.
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Introduction
Since the COVID-19 pandemic began in 
December 2019, and whilst waiting for an effec-
tive and safe vaccine, there has been increased 
urgency to achieve drug therapy with new and 
old drugs. Among the latter candidates is 25-hy-
droxyvitamin D (25(OH)D), which has been pro-
posed as a potentially modifiable risk factor for 
COVID-19 outcomes [1].
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25(OH)D is a steroid hormone, which comes 
mainly from the synthesis at the level of the 
skin, of a precursor that is 7-dehydrocholesterol, 
which due to the action of ultraviolet light (UVL) 
B (280–315 nm) exposure is converted into vita-
min D3 (cholecalciferol). In some countries at far 
latitudes, this origin is seasonal only [2]. 25(OH)
D can be obtained from diet (e.g., oily fish, eggs, 
liver) but very few commonly eaten foods contain 
sufficient amounts, which is why some countries 
(but only few) have a mandatory vitamin D food 
fortification policy [3]. The recommended amount 
of vitamin D intake in the majority of countries is 
10 μg or 400 IU of vitamin D daily during winter at 
least. Vitamin D levels can be affected by obesity, 
sunscreen, clothing, genetics, gender, smoking 
and socio-economic status [4]. Vitamin D2 (ob-
tained from dietary intake of mushrooms or some 
vegetables) and D3 (obtained from sun exposure 
or diet) are hydroxylated in the liver and kidneys 
where the active form of this vitamin is generated 
as, 1,25 Dihydroxycholecalciferol (1,25(OH)2D). 
Macrophages/dendritic cells and other organ 
cells also have the ability to convert 25 (OH) D 
to 1,25(OH)2D via CYP27B1. The biomarker of 
a patient’s VD status is the concentration of total 
25(OH)D (25-hydroxyvitamin D) concentration in 
serum, because vitamin D deficiency correlates 
better with 25(OH)D than with 1,25(OH)2D [5, 
6]. The effects of VD on calcium and phosphate 
absorption, osteoclast activation, and hence on 
bone calcification and muscle strength are widely 
known [7]. The VD receptor (VDR) is very widely 
expressed, including by all leucocyte classes, and 
it has been demonstrated that many genes are VD 
responsive [8], including  nearly two hundred 
genes in monocyte/macrophage cells [9]. Other 
research has shown that cytokine concentrations 
and proliferation of immune cells can be modu-
lated by VD [10].
Currently, research designs that have been 
used to postulate a relationship between hypovi-
taminosis D and the severity of SARS-CoV-2 in-
fection are either ecological, demographic with 
risk groups for VD deficiency (Mendelian random-
ization), or studies on the association of 25(OH)
D levels with the risk of having a positive test 
for the virus [1]. Ecological studies use databas-
es with information on 25(OH)D concentration 
of populations and countries and relate it to 
mortality, recovery, severity or susceptibility to 
SARS-CoV-2 infection. A published metanalysis 
that included ecological studies in 51 countries 
found no correlation between 25(OH)D levels and 
recovery or mortality rates [11]; however, consid-
ering latitude, an inverse relationship was found 
between mortality and 25(OH)D status in Asia, 
Middle East and Oceania; and surprisingly, in 
the USA and South America, the correlation was 
direct [12–14]. Ilie et al. found that the Pearson 
correlation coefficients between mean 25(OH)D 
levels and COVID-19 cases, and mean 25(OH)D 
levels and COVID-19 deaths per million popu-
lation were negative and statistically significant 
based on data from 20 European countries [15]; 
however, this study was re-analyzed by Kumar et 
al., adding to the model the life expectancy factor, 
and the result was the loss of the significance of 
25(OH)D levels as a predictor of mortality from 
COVID-19 [16].
Mendelian randomization studies use ge-
netic variants as markers to evaluate a causal 
relationship in observational data [17], and have 
been used in studies of the association between 
25(OH)D and severity of COVID-19 infection, 
based on the fact that the polymorphism of the 
VD receptor has an impact on the response to 
25(OH)D. Mendelian randomization studies use 
the genetic variant as a surrogate variable for 
25(OH)D deficiency, to infer the causal effect of an 
exposure [25(OH)D concentration] to an outcome 
(COVID-19 susceptibility, severity or mortality) 
[18].  Currently, 3 studies have been published 
using Mendelian randomization on the associa-
tion of 25(OH)D concentration with the risk or 
severity of COVID-19; one found a relationship 
[19]which impedes good immune function, is 
common during winter and spring in regions of 
high latitude. There is good evidence that vitamin 
D deficiency contributes to the seasonal increase 
of virus infections of the respiratory tract, from 
the common cold to influenza, and now possibly 
also COVID-19. This communication explores 
key factors that make it more likely, particularly 
in combination, that individuals are vitamin D 
deficient. These factors include old age, obesity, 
dark skin tone and common genetic variants that 
impede vitamin D status. Precision nutrition is an 
approach that aims to consider known personal 
risk factors and health circumstances to provide 
more effective nutrition guidance in health and 
disease. In regard to avoiding vitamin D deficien-
cy, people with excess body fat, a dark skin tone or 
older age usually need to use a moderately dosed 
daily vitamin D supplement, particularly those 
living in a high-latitude region, getting little ultra-
violet B exposure due to air pollution or staying 
mostly indoors. Carriers of the GC (group-specific 
component, but the other two did not [18, 20]. 
The limitations of this type of study is that it 
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uses a surrogate for 25(OH)D deficiency, and in 
severe cases of COVID-19, it is necessary to have 
the serum 25(OH)D concentration at the time of 
hospitalization for COVID-19; on the other hand, 
the polymorphism with which the individual was 
born does not predict numerous other factors that 
could have affected 25(OH)D status.  
The objective of the present study was to 
perform a systematic review and meta-analytic 
study on severity or mortality of SARS-CoV-2 in-
fection and 25-hydroxyvitamin D concentration 
based in observational studies and randomized 
clinical trials.
Material and methods
This study was conducted following the 
guidelines of the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) 
[21].
Search strategy
Two independent investigators performed 
a systematic search in PubMed, EMBASE, Google 
Scholar, preprint servers (medRxiv, bioRxiv and 
Research Square) and the Cochrane Database of 
Systematic Reviews for studies published be-
tween December 2019 and December, 2020. In ad-
dition, we conducted a secondary search based on 
the references lists of the retrieved articles. The 
PubMed search strategy is detailed in the Sup-
plementary file. 
Eligibility criteria
We searched for randomized controlled trials 
(RCTs) or observational studies reporting data 
on serum 25(OH)D concentration and SARS-
CoV-2 infection severity or mortality. We included 
studies in English or other (Russian and Spanish) 
language (all ages) meeting the following criteria: 
a) COVID-19 patients were diagnosed according 
to the interim guidance of the World Health 
Organization [22]; b) inclusion of the mean and 
standard deviation for laboratory test values of 
25(OH)D, and sample size with demographics, 
comorbidities, and complications; c) the study 
presented data on hazard ratios (HRs), relative 
risks (RRs), or odds ratios (ORs) with confidence 
intervals (CIs) or offered enough data to allow 
these to be calculated (including via email cor-
respondence with original authors if necessary); 
and d) SARS-CoV-2 infection severity criteria 
were described (generally defined as admission to 
intensive care unit, acute respiratory distress syn-
drome and/or need for mechanical ventilation). 
The following exclusion criteria were applied: 
reviews, abstracts, discussion summaries, and 
insufficient reported data including absence of 
vitamin D measurement.
Quality assessment
The quality of observational studies (cohort 
and case-control studies) and RCTs were assessed 
according to the Newcastle-Ottawa Quality As-
sessment Scale (NOS) [23] and the Cochrane Risk 
of Bias Assessment Tool [24], respectively. Two 
investigators evaluated the quality of the studies 
independently. Conflicting results were resolved 
by discussion and involvement of a third reviewer 
if necessary.
Data extraction
The following data were extracted from each 
study: authors, study location, year of publication, 
study design, number of participants, sex, age at 
baseline, serum VD level, outcome definition, and 
effect estimates with 95% confidence intervals 
(CIs). Targeted outcomes: COVID-19 mortality 
and/or severity proportions. Even though some 
studies have considered other 25(OH)D cut-off 
values  [25], in this study we defined Vitamin 
D deficiency as serum hydroxyvitamin D level 
<50 nmol/L (< 20 ng/mL) [26]. In a sub-analysis, 
more severe deficiency was defined as < 30 nmo-
l/L (< 12 ng/mL) [27].
Statistical analyses
Primary analyses evaluated the association 
(HRs, RRs or ORs) between 25-hydroxyvitamin 
D concentration and SARS-CoV-2 infection se-
verity or mortality. In the metaanalysis, in order 
to calculate the effect size of 25(OH)D concen-
tration and gender, the relative risk or odds ratio 
published by the authors of the included studies 
were used. We applied random effects with an 
inverse variance method to calculate the pooled 
RRs and 95% CIs according to the heterogeneity 
between the studies [28]. The overall estimates 
in the pooled analysis were obtained using Stata 
13 software (Stata Corp LP, College Station, TX).
Results
After screening 745 citations, 23 studies 
(5 cohort, 11 cases and controls, 7 cross sectional 
observational studies) were included (Figure 1), 
combining to a total sample of 2692 partici-
pants. The characteristics of the included studies 
are summarized in Table 1. The studies were from 
Belgium [29], China [30, 31], Germany [32], India 
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[33], Iran [34, 35], Italy [36–38], Philippines [39], 
Spain [40, 41], Switzerland [42], South Korea [43], 
Turkey [44, 45], Russia [46], The Netherlands [47], 
UK [48, 49] and USA [50,51]. Overall, mean age 
was 60.8 (SD 15.9) years and 53.8% were men. 
The mean NOS score of the included studies was 
8.1 (range: 7–9). The outcomes reported in the 
included papers are presented in Table 1.  
As shown in Figure 2, the metaanalysis sug-
gested that 25(OH)D < 50 nmol/L (< 20 ng/mL) 
was associated with an increased risk of severe 
disease (RR 2.00; 95% CI 1.47–2.71, 17 stud-
ies) and mortality (RR 2.45; 95% CI 1.24–4.84, 
13 studies). Only 7/23 papers reported C-reactive 
protein values, all of which were> 10 mg/L [31, 
38, 41, 44, 52–54].
Subgroup analyses were conducted to assess 
the effects of age, sex, and the alternative 25(OH)
D cut-off value (< 30 nmol/L) separately (Table 2). 
We found that the severity risk seemed higher in 
people < 60 years of age (p = 0.040, 4 studies). 
The severity risk seemed to increase as the cut-
off point for 25-hydroxyvitamin D concentration 
decreased (p = 0.025, 4 studies). Male sex (p < 
0.001, 7 studies) also had higher risk of severity 
and/or mortality. 
Two studies analyzed receiver operating 
characteristic (ROC) curve analyses to find the 
25(OH)D cut-off point with the highest sensitiv-
ity and specificity for the prediction of severity 
and/or mortality. Abrishami et al. (2020) found 
the cut-off point of < 62.5 nmol/L (< 25 ng/mL) 
to have a sensitivity of 75% and a specificity 
72%, for differentiating deceased and discharged 
patients [35]. Ye et al. (2020) observed that a cut-
off point of 41.19 nmol/L had a sensitivity of 87% 
and a specificity of 70% for predicting illness 
severity [30].
Discussion
The main finding of the present paper is that 
according to the included observational studies, 
25(OH)D deficiency (serum 25-hydroxyvitamin D 
concentration < 50 nmol/L) was associated with 
an increased risk of severe disease and mortality 
from SARS-CoV-2 infection. Our findings do not 
imply causation because they only summarize 
the conclusions of observational studies. For 
example, it is not possible to extrapolate that in 
acute patients with COVID-19 who have hypovita-
minosis D, the immediate replacement of vitamin 
Figure 1. Flowchart of the included studies
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Figure 2. A. Forest plot of the metaanalysis of the association between mortality from SARS-CoV-2 infection and 25-hydroxyvitamin D concen-
tration (< 50 nmol/L); B. Forest plot of the metaanalysis of the association between severity of SARS-CoV-2 infection and 25-hydroxyvitamin D 
concentration (< 50 nmol/L). Analysis model: random effects. CI — confidence interval; RR — relative risk
A
B
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D could improve the prognosis [55]. Another im-
portant finding is that there is the possibility that 
the low concentrations of 25(OH)D reported are 
an epiphenomenon of the inflammatory process 
associated with severe SARS-CoV-2 infection, 
although only 7/23 studies reported C-reactive 
protein values, all of which were > 10 mg/L.
We found that the severity risk seemed higher 
in people younger than 60 years of age; how-
ever, this finding related to only 4 studies and 
had a marginal P value. Our conclusion that the 
severity risk seemed to increase as the cut-off 
point for 25(OH)D concentration decreased adds 
biological plausibility to the findings. In addition, 
higher male risk profile, as clinically expected, is 
given the known epidemiology of COVID-19 in-
fection [56]. It has to be noted that a tradeoff 
between our two outcomes exists, as very severe 
cases who died were counted as mortality and 
not severity for the purpose of association with 
25(OH)D status. 
The findings of the present study can be 
compared with similar meta-analytical studies 
and others published prior to the pandemic, on 
risk associated with severity of acute respiratory 
infections. Ghasemian et al. (2020) and Chen et 
al. (2020) published two meta-analytic studies 
where they found an association between 25(OH)
D deficiency and insufficiency with mortality 
from SARS-CoV-2 infection; however, ecological 
studies have the limitation that the reported 
mortality could have varied in each of the coun-
tries, as the pandemic evolved [12, 57]. Another 
meta-analytic study (5 articles included) found 
a mean 25(OH)D concentration of  18 ng/mL 
in severe COVID-19 cases (95% CI: 1–35) and 
26 ng/mL in non-severe cases (95% CI: 23.9–28.7) 
[11]. Pereira et al. (2020) noted that a 25(OH)D 
concentration of < 50 nmol/L was associated with 
an increased risk of hospitalization (3 studies) 
and mortality from COVID-19 (5 studies) [58]. 
In a systematic study (7 papers), Munshi et al. 
(2020) found that patients with poor prognosis 
had significantly lower serum concentrations of 
25(OH)D compared to those with good progno-
sis, representing an adjusted standardized mean 
difference of -5.12 (95% Cl = -9.14 to -1.10, p 
= 0.012) [59]. Pham et al. (2020) published in 
2019 a meta-analytic study where they found 
that a 25(OH)D concentration of <50 nmol/L was 
inversely associated with risk and severity of 
acute respiratory tract infection [60]. Zhou et al. 
published a meta-analytical study in 2019 where 
they documented an increased risk of communi-
ty-acquired pneumonia in patients with 25(OH)
D deficiency (< 50 nmol/L) [61]. Martineau et 
al. published in 2017 a meta-analytic study with 
25 randomized clinical trials, finding that vitamin 
D supplementation reduced the frequency of 
acute respiratory infection; however, the benefit 
was greater in those  who were receiving daily 
or weekly 25(OH)D, and protective effects were 
Table 2. Association between severity of SARS-CoV-2 infection and serum 25-hydroxyvitamin D concentration: summary 
of subgroup analyses
Subgroup Studies (n) RR (95% CI) P
Severity
Cut point 25-hydroxyvitamin D concentration [nmol/L]
  < 30
  < 50
Mortality
Cut point 25-hydroxyvitamin D concentration [nmol/L]
  < 30















  < 60
  ≥ 60
Mortality
Mean age [years]*
  < 60






















*One study (Alipio et al. 2020) did not report mean age data
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stronger in those with baseline 25-hydroxyvi-
tamin D concentrations < 25 nmol/L; and the 
benefit was not significant in those who received 
bolus doses [62]. 
The possible mechanisms that could ex-
plain the inverse relationship between the con-
centration of 25(OH)D and the frequency of 
presentation of severe forms of SARS, would 
be its angiotensin-converting enzyme 2 (ACE2) 
down-regulation, regulation of IL-6 and preven-
tion of hypocalcemia. Mok et al. in in vitro studies 
with Vero E6 cells (African green monkey kidney 
cells) and hNECs (human nasal epithelial cells) 
found that calcitriol, the active form of vitamin 
D, has potent activity against SARS-CoV-2; the 
hypothesis of the possible mechanism of antiviral 
action would be in the post-entry phase of viral 
replication [63]. The mechanism of entry into hu-
man cells of SARS-CoV-2 is through ACE2, which 
is part of the renin-angiotensin system (RAS). It 
has been postulated that 25(OH)D would have 
a possible mechanism of protection against acute 
lung injury (ALI) / acute respiratory distress syn-
drome (ARDS), through a negative endocrine RAS 
modulator which inhibits renin expression and 
generation. This mechanism would be carried out 
by its inducing action of ACE2 / Ang- (1-7) / MasR 
axis activity and inhibits renin and the ACE / Ang 
II / AT1R axis, thereby increasing expression and 
concentration of ACE2, MasR and Ang-(1–7) [64]. 
Recently, high levels of ACE have been found in 
patients with severe COVID-19 with low 25(OH)D 
concentrations [34]; these findings are compatible 
with the harmful effect of high levels of ACE in 
Ang II generation and promote the detrimental 
effects of the AT1R classical axis (inducing vaso-
constriction, inflammation, oxidative stress, and 
cell proliferation). 
Recently, a systematic review found a cor-
relation between premorbid levels of IL-6 and 
mortality from COVID-19; additionally, the re-
viewed studies reported concomitant decrease in 
25(OH)D concentrations [65]. On the other hand, 
one of the known actions of concentrations is to 
modulate the activity of IL-6; therefore, poten-
tially, the control of hypovitaminosis D could 
reduce the risk of presentation of severe forms 
of COVID-19 [65]. McGregor et al. (2020) found 
that CD4+ T cells in the bronchoalveolar lavage 
fluid (BALF) of patients with COVID-19 are Th1-
skewed and that VDR is among the top regulators 
of genes induced by SARS-CoV-2 [66]. Part of 
the pathophysiology associated with cytokine 
storm is due to suppression of Th1 cooperative 
responses, which favors the Th2 type with exces-
sive release of tumor necrosis alpha (TNF-alpha) 
and interleukins. 25(OH)D causes epigenetic 
re-modelling, induces and recruits a set of TFs 
(transcription factor), including STAT3 (signal 
transducer and activator of transcription 3), c-JUN 
and BACH2 (BTB Domain And CNC Homolog 2) 
that collectively repress Th1 and Th17 programs 
and induces IL-10 via IL-6-STAT3 signaling [66]. 
Recently, a significant increase in inflammation 
markers (IL-6, TNFa and serum ferritin levels) has 
been reported in critically ill COVID-19 patients 
deficient in 25(OH)D (< 50 nmol/L) [33]. Medi-
cal College the current study was undertaken as 
continuous prospective observational study of 
6 weeks. Participants were COVID-19 patients 
of age group 30–60 years admitted during the 
study period of 6 weeks. Study included either 
asymptomatic COVID-19 patients (Group A. Sun 
et al. (2020) found that 74% of patients admitted 
for severe COVID-19 had hypocalcemia and low 
concentrations of 25(OH)D and hypoproteinemia, 
and for these reasons they propose hypocalcemia 
as a biomarker of clinical severity and prognosis 
[67]. Actually, the studies on the relationship 
between the concentration of 25(OH)D and SARS-
CoV-2 infection are showing that there is a dis-
turbed parathyroid-vitamin-D axis, which would 
last up to 8 weeks after the discharge of a patient 
with SARS-CoV-2 infection with hypovitamino-
sis D [68]we aimed to investigate associations of 
VITD status to disease presentation within the 
CovILD registry. This prospective, multicenter, 
observational study on long-term sequelae in-
cludes patients with COVID-19 after hospital-
ization or outpatients with persistent symp-
toms. Eight weeks after PCR confirmed diagnosis, 
a detailed questionnaire, a clinical examination, 
and laboratory testing, including VITD status, 
were evaluated. Furthermore, available laboratory 
specimens close to hospital admission were used 
to retrospectively analyze 25-hydroxyvitamin D 
levels at disease onset. A total of 109 patients 
were included in the analysis (60% males, 40% 
females.
It is important to discuss whether low con-
centrations of 25(OH)D in patients with severe 
COVID-19 infection is a cause or consequence 
of severe COVID-19 infection, for three main 
reasons: absence of baseline 25(OH)D measure-
ment before infection, prior knowledge that the 
concentration of 25(OH)D decreases as a conse-
quence of an inflammatory process, and most of 
the studies described on this association did not 
report the concentration of C-reactive protein 
(CRP) together with that of 25(OH)D. Before the 
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COVID-19 pandemic, it was known that 25(OH)
D concentration decreases as a consequence of 
an inflammatory state, that is, it is considered 
a negative acute phase reactant  [69–71] . Addi-
tionally, it has been described that this decrease 
in 25(OH)D during these inflammatory processes 
can persist for up to 3 months [70]. It has been 
recommended that a reliable clinical interpreta-
tion of the 25(OH)D concentration can be made 
only if the C-reactive protein (CRP) is < 10 mg/L 
[71], because it has been described that 25(OH)
D concentrations are inversely correlated with 
CRP concentrations [72]. The mechanism in-
volved in the decrease in serum 25(OH)D during 
an acute inflammatory state would be associated 
with the decrease in vitamin D binding protein 
(VDBP) and increased urinary loss of VDBP that 
occurs in a systemic inflammatory response (SIR) 
[69, 70]. In the present paper, only 7/23 studies 
reported the concentration of C-reactive protein 
(CRP), and in all of which it was > 10 mg / L. [31, 
38, 41, 44, 52–54], therefore, there would be the 
possibility that one of the causes of the reported 
decrease in 25(OH)D is an epiphenomenon of the 
inflammatory process of SARS-CoV-2. Regardless 
of whether it is its cause or effect, measurement 
of 25(OH)D concentration should be considered 
a marker of inflammation, in addition to markers 
for inflammation and tissue damage in prognostic 
models for COVID-19 [29].
The present metaanalysis has its limitations, 
the main one being that it is based on observation-
al studies and not on interventional studies such 
as randomized controlled clinical trials. Addition-
ally, the studies used different methodologies to 
assess 25(OH)D status (e.g. LC-MS/MS, ELISA). 
It is important to emphasize that no causality 
can be inferred from our results. However, evi-
dence from observational studies is better than 
that based on the ecological ones. A limitation 
is that many studies did not report if the 25(OH)
D concentration was measured before or during 
COVID-19 infection, but in the future there may 
be scope for analyzing vitamin D in hair to solve 
this issue [73]the number of requests for vitamin 
D measurement keeps dramatically increasing 
year-on-year. Currently, the recognised best mark-
er of vitamin D status is the concentration of the 
25-hydroxyvitamin D (25(OH. Indeed, it is im-
portant to investigate whether SARS-CoV-2 infec-
tion, especially the severe forms, cause a decrease 
in the concentration of 25(OH)D, in patients 
who previously had them at normal levels. On 
the other hand, there is a possible ‘healthy user 
effect’ confounder, that is, higher concentrations 
of 25(OH)D could be seen in people who eat well, 
have healthy lifestyles and spend more time out-
doors exposed to sunlight, which in turn makes 
them more generally resilient in the face of any 
acute illness [74]. In other words, 25(OH)D status 
could be epiphenomenally associated with SARS-
CoV-2 outcomes. 
 In conclusion, at present the evidence avail-
able supports the hypothesis of increased SARS-
CoV-2 risk of infection severity and mortality in 
patients with 25(OH)D deficiency (< 50 nmol/L). 
Our findings do not imply causality but support 
further research in this area, including the con-
duct of robustly designed randomized controlled 
trials. On the other hand, new studies should 
be designed to determine if decreased 25(OH)D 
is an epiphenomenon or consequence of the in-
flammatory process associated with severe forms 
of SARS-CoV-2.  Meanwhile, the concentration 
of 25(OH)D could be considered as a negative 
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